Latest Ivf News

Memphasys has locked in a 12-month exclusive supply agreement with Monash IVF for its Felix™ sperm selection system, marking its biggest commercial contract to date and setting a foundation for recurring revenue.

Monash IVF lowers its FY26 underlying NPAT guidance to $17-18 million, citing a 4.7% drop in Australian stimulated IVF cycles. Despite this, the company has expanded its national market share to 20.1% and seen international volume growth.

Memphasys has inked its first exclusive commercialization agreement in South-East Asia with TMSC Vietnam, targeting the fast-growing Vietnamese IVF sector with its Felix™ sperm separation system. The two-year contract, valued at A$530,000, hinges on regulatory approval expected by August 2026.

Memphasys has landed a major 1,000-cartridge order for its Felix™ System from MENA distributor ITL, with strong repeat demand from Qatar’s Hamad Medical Corporation and new market expansions into UAE, Kuwait, and soon Turkey.

Monash IVF has turned down a revised $0.90 per share acquisition proposal from a consortium led by Genesis Capital and WHSP Holdings, citing significant undervaluation and confidence in its new CEO’s growth strategy.

Memphasys Limited has marked a milestone quarter with revenue surpassing A$100,000, driven by repeat orders and multi-year contracts, signalling its transition to a commercially focused biotech business.

Monash IVF has received a revised $0.90 per share acquisition proposal from a consortium led by Genesis Capital and WHSP Holdings, upping the ante from a previous $0.80 offer. The deal hinges on exclusivity and unanimous board support, with no guarantee of completion.

Memphasys Limited (ASX: MEM) announced an investor webinar and released an updated presentation detailing its transition from early-stage commercialisation to scaling global revenues, highlighting multi-market sales, recurring cartridge revenue, and regulatory progress.

Memphasys Limited confirms uninterrupted operations across the Middle East and North Africa, securing new orders and advancing regulatory approvals despite ongoing regional tensions.

Memphasys Limited has advanced its Felix™ System commercial rollout with key regulatory approvals and new international contracts, while trimming operating costs and narrowing losses in the first half of FY2026.

Memphasys Limited has secured Therapeutic Goods Administration approval for its Felix™ System two months ahead of schedule, enabling immediate commercial sales and clinical use in Australia.

Memphasys has lodged regulatory submissions for its Felix™ System in Australia and India, following CE Mark approval, while progressing UK market entry under the CE Mark transition framework.